AXLRx Book a callCommission

Big Pharma · Company profile

Novo Nordisk

Commission a Novo Nordisk report

By therapy area

Therapy area All areas Metabolic

AXLRx reports featuring Novo Nordisk

CI · Metabolic · CI Team · Launch Lead US MASH Competitive Intelligence Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window. US · In-Market · Read report → CI · Metabolic · CI Team · Launch Lead US Obesity Competitive Intelligence Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality. US · In-Market · Read report → CI · Metabolic · CI Team · Launch Lead US Type 2 Diabetes Competitive Intelligence Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US MASH Disease Landscape The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US Type 2 Diabetes Disease Landscape 38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US Obesity Disease Landscape US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage. US · In-Market · Read report →